LetterEpidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): Experience of a tertiary medical center
Components of this work were presented at the 2014 Medical Dermatology Society Meeting in Denver, CO, on March 20, 2014, and at the 2014 Society for Investigative Dermatology Meeting in Albuquerque, NM, on May 9, 2014.
References (4)
- et al.
The prevalence of metabolic syndrome in patients with hidradenitis suppurativa
J Am Acad Dermatol
(2014) - et al.
Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies
J Am Acad Dermatol
(2013)
There are more references available in the full text version of this article.
Cited by (0)
Supported by the Department of Dermatology, Brigham and Women's Hospital.
Disclosures: Dr Merola is an investigator for Amgen, Pfizer, and Biogen Idec; is a consultant for Biogen Idec; serves on the advisory board of Amgen, Eli Lilly, and Novartis; has a licensed outcome measure to Abbvie; and is a speaker for Abbvie. Dr Qureshi serves as a consultant for Abbvie, Amgen, Centers for Disease Control and Prevention, Janssen, Merck, Novartis, and Pfizer and is an investigator for Amgen. Drs Patel, Wright, and Vleugels and Mr Cohen have no conflicts of interest to declare.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.